MX367260B - Tabletas de rucaparib de dosificación elevada. - Google Patents
Tabletas de rucaparib de dosificación elevada.Info
- Publication number
- MX367260B MX367260B MX2017001540A MX2017001540A MX367260B MX 367260 B MX367260 B MX 367260B MX 2017001540 A MX2017001540 A MX 2017001540A MX 2017001540 A MX2017001540 A MX 2017001540A MX 367260 B MX367260 B MX 367260B
- Authority
- MX
- Mexico
- Prior art keywords
- rucaparib
- high dosage
- tablet
- dosage strength
- strength tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040849P | 2014-08-22 | 2014-08-22 | |
| US201562101739P | 2015-01-09 | 2015-01-09 | |
| PCT/US2015/045522 WO2016028689A1 (en) | 2014-08-22 | 2015-08-17 | High dosage strength tablets of rucaparib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001540A MX2017001540A (es) | 2017-05-11 |
| MX367260B true MX367260B (es) | 2019-08-12 |
Family
ID=55347324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001540A MX367260B (es) | 2014-08-22 | 2015-08-17 | Tabletas de rucaparib de dosificación elevada. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9987285B2 (enExample) |
| EP (1) | EP3182975B1 (enExample) |
| JP (3) | JP6574477B2 (enExample) |
| KR (2) | KR20170043597A (enExample) |
| CN (2) | CN106794185A (enExample) |
| AU (2) | AU2015305696B2 (enExample) |
| BR (1) | BR112017000865A2 (enExample) |
| CA (1) | CA2955495C (enExample) |
| DK (1) | DK3182975T3 (enExample) |
| ES (1) | ES3048688T3 (enExample) |
| FI (1) | FI3182975T3 (enExample) |
| HR (1) | HRP20251484T1 (enExample) |
| IL (1) | IL249946B (enExample) |
| LT (1) | LT3182975T (enExample) |
| MX (1) | MX367260B (enExample) |
| NZ (1) | NZ728392A (enExample) |
| PL (1) | PL3182975T3 (enExample) |
| PT (1) | PT3182975T (enExample) |
| RS (1) | RS67356B1 (enExample) |
| RU (1) | RU2705156C2 (enExample) |
| SG (1) | SG11201700265VA (enExample) |
| SI (1) | SI3182975T1 (enExample) |
| SM (1) | SMT202600141T1 (enExample) |
| WO (1) | WO2016028689A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| KR20170043597A (ko) * | 2014-08-22 | 2017-04-21 | 클로비스 온콜로지 인코포레이티드 | 루카파립의 고 용량 강도 정제 |
| CN106008530B (zh) * | 2016-07-24 | 2018-06-26 | 石家庄久正生物科技有限公司 | 一种抗卵巢癌药物Rucaparib关键中间体的制备方法 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| EP3573990B1 (en) | 2017-01-24 | 2024-07-10 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| CN111278433A (zh) * | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| AU2019205325A1 (en) | 2018-01-05 | 2020-08-13 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
| CN108853030B (zh) * | 2018-09-26 | 2021-10-01 | 上海朝晖药业有限公司 | 一种治疗恶性肿瘤的药物制剂及其制备方法 |
| WO2020113500A1 (zh) * | 2018-12-06 | 2020-06-11 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
| KR20220035925A (ko) | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
| ES3014370T3 (en) | 2020-04-28 | 2025-04-22 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| ES3051838T3 (en) | 2020-07-14 | 2025-12-30 | Assia Chem Ind Ltd | Solid state forms of rucaparib salts |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2022215034A1 (en) | 2021-04-08 | 2022-10-13 | Rhizen Pharmaceuticals Ag | Inhibitors of poly(adp-ribose) polymerase |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| CN118215467A (zh) * | 2021-11-10 | 2024-06-18 | 克里蒂泰克公司 | 鲁卡帕尼颗粒及其用途 |
| WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1140936B1 (en) | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
| JP2006522088A (ja) | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩 |
| MXPA06000993A (es) | 2003-07-25 | 2006-08-31 | Cancer Rec Tech Ltd | Inhbidores triciclicos de parp. |
| JP2008513435A (ja) | 2004-09-22 | 2008-05-01 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物 |
| CA2580833C (en) | 2004-09-22 | 2010-12-21 | Pfizer, Inc. | Method of preparing poly(adp-ribose) polymerases inhibitors |
| CA2581025C (en) | 2004-09-22 | 2011-06-07 | Pfizer Inc. | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| US20110136883A1 (en) * | 2008-04-09 | 2011-06-09 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| ES2607806T5 (es) * | 2010-02-12 | 2024-10-07 | Pfizer | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona |
| CN104582795B (zh) | 2012-04-05 | 2018-04-20 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| KR20170043597A (ko) | 2014-08-22 | 2017-04-21 | 클로비스 온콜로지 인코포레이티드 | 루카파립의 고 용량 강도 정제 |
-
2015
- 2015-08-17 KR KR1020177007284A patent/KR20170043597A/ko not_active Ceased
- 2015-08-17 ES ES15833096T patent/ES3048688T3/es active Active
- 2015-08-17 SM SM20260141T patent/SMT202600141T1/it unknown
- 2015-08-17 BR BR112017000865A patent/BR112017000865A2/pt not_active Application Discontinuation
- 2015-08-17 DK DK15833096.9T patent/DK3182975T3/da active
- 2015-08-17 LT LTEPPCT/US2015/045522T patent/LT3182975T/lt unknown
- 2015-08-17 CN CN201580042815.9A patent/CN106794185A/zh active Pending
- 2015-08-17 NZ NZ728392A patent/NZ728392A/en unknown
- 2015-08-17 MX MX2017001540A patent/MX367260B/es active IP Right Grant
- 2015-08-17 FI FIEP15833096.9T patent/FI3182975T3/fi active
- 2015-08-17 RU RU2017109139A patent/RU2705156C2/ru active
- 2015-08-17 PT PT158330969T patent/PT3182975T/pt unknown
- 2015-08-17 US US14/828,065 patent/US9987285B2/en active Active
- 2015-08-17 AU AU2015305696A patent/AU2015305696B2/en active Active
- 2015-08-17 SI SI201532081T patent/SI3182975T1/sl unknown
- 2015-08-17 WO PCT/US2015/045522 patent/WO2016028689A1/en not_active Ceased
- 2015-08-17 CA CA2955495A patent/CA2955495C/en active Active
- 2015-08-17 PL PL15833096.9T patent/PL3182975T3/pl unknown
- 2015-08-17 EP EP15833096.9A patent/EP3182975B1/en active Active
- 2015-08-17 HR HRP20251484TT patent/HRP20251484T1/hr unknown
- 2015-08-17 RS RS20251082A patent/RS67356B1/sr unknown
- 2015-08-17 CN CN202110458329.2A patent/CN113209033A/zh active Pending
- 2015-08-17 JP JP2017510539A patent/JP6574477B2/ja active Active
- 2015-08-17 KR KR1020237020594A patent/KR102803917B1/ko active Active
- 2015-08-17 SG SG11201700265VA patent/SG11201700265VA/en unknown
-
2017
- 2017-01-05 IL IL249946A patent/IL249946B/en active IP Right Grant
-
2018
- 2018-03-14 US US15/920,643 patent/US10130636B2/en active Active
- 2018-10-08 US US16/154,038 patent/US20190099430A1/en not_active Abandoned
-
2019
- 2019-08-15 JP JP2019149084A patent/JP6797980B2/ja active Active
- 2019-11-29 AU AU2019272064A patent/AU2019272064B2/en active Active
-
2020
- 2020-11-18 JP JP2020191356A patent/JP7127101B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001540A (es) | Tabletas de rucaparib de dosificacion elevada. | |
| HUS2200054I1 (hu) | 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| PH12017500802A1 (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
| CL2016002310A1 (es) | Nuevos compuestos bicíclicos. | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| SI3152212T1 (sl) | Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike | |
| IL248546A0 (en) | A polysubstituted fluorine compound as a proton tyrosine kinase inhibitor | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| UA111804C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK) | |
| CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MX381819B (es) | Derivados de heterociclico opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias. | |
| SI3596080T1 (sl) | Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati | |
| WO2016073771A3 (en) | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors | |
| GEP20186934B (en) | Quinolizinone derivatives as pi3k inhibitors | |
| PT3102187T (pt) | Composições farmacêuticas estáveis contendo sitagliptina sob a forma de comprimidos de libertação imediata | |
| MX2017008931A (es) | Formulaciones farmaceuticas de xantina o derivados de xantina. | |
| PH12016502540A1 (en) | Pharmaceutical dosage forms | |
| HK1236034A1 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
| HK1236035A1 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |